Intensity Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -1.09 | -0.96 | +12.19% |
| 2025-11-06 | -1.50 | -1.50 | — |
| 2025-08-07 | -4.50 | -3.25 | +27.78% |
| 2025-05-13 | -3.25 | -5.50 | -69.23% |
| 2025-03-13 | -5.75 | -5.50 | +4.35% |
| 2024-11-13 | -7.62 | -6.25 | +18.03% |
| 2024-08-08 | -8.00 | -9.00 | -12.50% |
| 2024-05-09 | — | -8.50 | — |
| 2024-03-14 | -4.50 | -3.00 | +33.33% |
| 2023-11-13 | -2.25 | -4.25 | -88.89% |
| 2023-08-14 | -10.00 | -26.25 | -162.50% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| INTS | -15.41% | -41.62% | -57.17% | -63.03% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -18.38% | -36.98% | -53.73% | -75.72% |